346003-5MG Display Image

Glucagon Receptor Antagonist II

Code: 346003-5MG D2-231

Biochem/physiol Actions

Reversible: no

Product does not compete with ATP.

Primary TargetGlucagon Receptor

Target IC50: 3.7 nM, 63 nM, and 60 nM f...


read more

Your Price
£160.00 EACH

Biochem/physiol Actions

Reversible: no

Product does not compete with ATP.

Primary TargetGlucagon Receptor

Target IC50: 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively

Cell permeable: yes

General description

A cell-permeable triarylpyrrole compound that acts as a selective, non-competitive, high affinity glucagon receptor antagonist (IC50 = 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively). Exhibits diminished antagonistic properties in the presence of Mg2+ (by ≥ 20-fold) and exhibits poor affinity for the rat, guinea pig, and rabbit glucagon receptors (IC50 >1 µM). Does not inhibit binding of glucagon-like peptide-1 (GLP-1) to the homologous GLP-1 receptor even at concentrations as high as 10 µM. Does not affect ligand binding of a panel of other GPCRs and only weakly affects p38 kinase activity (IC50 = 1.44 µM). Potently inhibits glucagon-induced GTPγS binding to Gαs (IC50 = 158 nM) and adenylate cyclase activation in hGLUR-CHO cells (Kb = 25 nM). Shown to be orally bioavailable in both mice and rats.

A cell-permeable triarylpyrrole compound that acts as a selective, non-competitive, high affinity glucagon receptor antagonist (IC50 = 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively). Exhibits diminished antagonistic properties in the presence of Mg2+ (by ≥20-fold) and exhibits poor affinity for the rat, guinea pig, and rabbit glucagon receptors (IC50 >1 µM). Does not inhibit binding of glucagon-like peptide-1 (GLP-1) to the homologous GLP-1 receptor even at concentrations as high as 10 µM. Does not affect ligand binding of a panel of other GPCRs and only weakly affects p38 kinase activity (IC50 = 1.44 µM). Potently inhibits glucagon-induced GTPγS binding to Gαs (IC50 = 158 nM) and adenylate cyclase activation in hGLUR-CHO cells (Kb = 25 nM). Shown to be orally bioavailable in both mice and rats.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Dallas-Yang, Q., et al. 2002. Anal. Biochem.301, 156.Cascieri, M.A., et al. 1999. J. Biol. Chem.274, 8694.de Laszlo, S.E., et al. 1999. Bioorg. Med. Chem. Lett.9, 641.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)

assay≥98% (HPLC)
colorlight beige
formsolid
manufacturer/tradenameCalbiochem®
Quality Level100
shipped inambient
solubilityDMSO: 45 mg/mL, ethanol: 45 mg/mL
storage conditionprotect from light, OK to freeze
storage temp.2-8°C
Cas Number191034-25-0
Quantity
Est. Dispatch/Availability